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The onset or exacerbation of psoriasis, a T-cell-depen-
dent skin disease with autoimmune features, can be
triggered by drugs such as antimalarials and beta-
blockers. Xenobiotics may also play a role in idiopathic
psoriasis. It has been hypothesized that di¡erent meta-
bolic e⁄ciencies caused by variant alleles of xenobiotic
metabolizing enzymes could lead to the accumulation
of xenobiotics or their reactive metabolites in target or-
gans. Subsequently, neoantigens or cryptic peptides
could be presented and initiate an aggressive T cell re-
sponse. In this context, we analyzed a broad array of xe-
nobiotic metabolizing enzymes in up to 327 Caucasian
psoriasis patients and compared them to 235 control
persons. Alleles tested include four phase I and three
phase II enzymes. Signi¢cantly more carriers of the
variant alleles of CYP1A1 (alleles n2A and n2C) were
found in healthy controls than in patients, suggesting a
protective role for these alleles. No signi¢cant di¡erence
between patients and controls could be found, however,
for the other phase I alleles 1B1 n1 and 1B1 n3, 2C19 n1A
and 2C19 n2A, and 2E1 n1A and 2E1 n5B. Of the variant
alleles coding for phase II enzymes only GSTM1, but
not GSTT1 or NQOR, correlated with a risk to contract
psoriasis. Some combinations of phase I and phase II
enzymes suggested protective or risk-associated e¡ects.
Interestingly, heterozygosity for CYP2C19 alleles n1A
and n2Awas associated with increased risk for ‘‘late on-
set’’ psoriasis, whereas this genotype was protective for
psoriatic arthritis. This is the ¢rst large-scale study on
these enzymes and the results obtained support
the concept that di¡erent activities of metabolizing
enzymes can contribute to disease etiology and
progression. Key words: autoimmunity/human/immunotox-
icology/susceptibility genes/xenobiotic metabolism. J Invest
Dermatol 120:765 ^770, 2003
P
soriasis, a¡ecting about 2% of Caucasians, is an idio-
pathic chronic in£ammatory disease of the skin with
autoimmune features. Psoriasis is characterized by a
marked hyperproliferation of keratinocytes in associa-
tion with vascular expansion, leukocyte in¢ltration,
and altered cytokine production (Valdimarsson et al, 1986; Kapp,
1993; Ortonne, 1996). Psoriasis has a genetic basis, although the
mode of inheritance (e.g., dominant/recessive) remains unclear.
Concordance in monozygotic twins is not absolute with 63%^
70%, pointing to environmental factors in addition to genetic
factors in the onset and severity of the disease (Farber et al, 1974;
Bhalerao and Bowcock, 1998). Reports on associations with en-
vironmental components include infections, endocrine factors,
and drugs. Lithium, antimalarials, beta-blockers, ACE inhibitors,
nonsteroidal anti-in£ammatory drugs, terbina¢ne, cigarette
smoking, and heavy consumption of alcohol have been found to
provoke or exacerbate psoriasis, although evidence is often anec-
dotal and not epidemiologically secured (Rosenberg and Belew,
1982; Abel et al, 1986; Kruger and Duvic, 1994; Baker, 2000).With
respect to autoimmune diseases the impact of environmental fac-
tors such as drugs, infections, and others is conceivably mediated
by direct or indirect e¡ects on compartments of the immune sys-
tem, which may result in de novo immunogenicity of self-proteins
(Griem et al, 1997). Chemical compounds or their metabolites can
become immunogenic in two ways: either they can attach to a
peptide and be presented along with that peptide, or by binding
to cellular proteins they can change the normal breakdown of
those proteins in antigen processing, leading to the presentation
of cryptic peptides and subsequent T cell activation. An example
of the former mode, leading to allergic drug reaction, is presenta-
tion of penicillin toTcells (Weltzien and Padovan, 1998). Protein-
reactive oxidation forms of gold salts represent an example of the
latter (Griem et al, 1996), where new self-antigens are generated
and become available against which the immune system is not
tolerant. Adverse immune reactions to self, e.g., unresolvable in-
£ammation, can then be the consequence. Xenobiotic metaboliz-
ing enzymes (XMEs) play a central role for the occurrence of
neoantigens because they control the breakdown pathways and
kinetics for the metabolism of endogenous and exogenous
chemical substances. In humans, allelic forms of many XMEs
are known, often resulting in changed e⁄ciencies of that parti-
cular XME. In consequence, this may result in genetically con-
trolled preferential generation of protein-reactive metabolites or
a longer persistence (and thus availability) of a protein-reactive
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substance in the body, which conceivably can translate into
immunogenicity of that substance. For instance, this has been
shown in man and mice where slow acetylators easily elicit an
immune response against procainamide, whereas fast acetylators
are less susceptible (Uetrecht and Woosley, 1981; Wolkenstein
et al, 1995).
Small chemical compounds like the drugs mentioned above
are conspicuous in eliciting or exacerbating psoriasis and have
been suggested to play a role in the T cell response (Rosenberg
and Belew, 1982; Halevy and Livni, 1993). By analyzing allelic var-
iants of a wide range of XMEs in a large group of patients su¡er-
ing from psoriasis we therefore wanted to test the hypothesis that
the genetic setup of XMEs is linked to psoriasis.
MATERIALS AND METHODS
Study population Three hundred and twenty-seven psoriatic patients
attending dermatology clinics in Dˇsseldorf, Bad Bentheim, and Bad
Salzschlirf, all in Germany, participated. Only a very small number of the
patients that we approached reneged. Two hundred and thirty-¢ve healthy
control subjects were recruited from voluntary blood donors in Frankfurt/
Main, Germany, and through an unrelated study in Dortmund, Germany.
Written informed consent was obtained from all subjects. The study was
approved by the ethical committee at the University of Dˇsseldorf. All
subjects were Caucasians (here, Germans). Genomic DNA was isolated
from 5 ml blood samples with a commercial isolation kit (Boehringer,
Mannheim, Germany).
Genotyping for reference sequences and allelic variants We use the
terms reference sequence (RefS) and variant sequence (VarS) throughout
this report. Usually the reference sequence is the ¢rst allele described or
the most common one.
Cytochromes P450 CYP1A1 n2A, CYP1B1, CYP2C19, and CYP2E1,
and NQOR (synonyms: DT diaphorase, quinone oxidoreductase), and
the glutathione-S-transferases hGSTM1 and hGSTT1 were typed on the
genomic DNA. With the exception of the glutathione-S-transferases,
allelic variants were identi¢ed by restriction fragment length poly-
morphism after appropriate restriction enzyme digestion of the polymerase
chain reaction (PCR) fragment (RFLP-PCR). Positive controls with DNA
of known genotype were included each time, and random samples were
typed several times. Table I lists primer sequences, PCR conditions, and
restriction digest enzymes.
The GSTM1 and GSTT1 alleles were analyzed by multiplex PCR as
described elsewhere (Wiebel et al, 1999), and depending on the presence or
absence of the respective DNA bands the study subjects were categorized as
homozygous null (VarS) or carrier of the gene (RefS). The CYP1A1 allele
n2C was analyzed in a LightCycler (RocheTM; Wittwer et al, 1997). Outer
primers were used to amplify the gene, and £uorescent primers covering
the site of base exchange were added. The melting curves then identify
RefS and VarS. LightCycler primer sequences are given inTable II.
Nomenclature The following nomenclature was used to describe the
di¡erent polymorphic variants (Garte et al, 2001a; Ingelman-Sundberg
et al, 2001). For the CYP1A1 polymorphisms the genotype is CYP1A1
n1A/n1A for the reference sequence. The CYP1A1 n2A allele has a
3801T4C exchange (allele also known as Msp); CYP1A1 n2C allele has a
2455A4G exchange (allele also known as IVA). CYP1A1 n2B is the name
of the allele if both of these exchanges are at the same locus; we did not
determine this allele here. For the CYP1B1 locus allele the reference allele is
called n1, and the 4326C4G (Val432Leu) polymorphism is called n3. For
CYP2C19 and CYP2E1 the reference allele is called n1A, and the
polymorphic variants are called n2A (681G4A) and n5B (^1293G4C and
^1053C4T), respectively. The GSTM1 1n/1n and GSTM1 1n/n2 are referred
to as carriers, with GSTM1 n2/n2 genotype used to indicate the
homozygous null variant. Similarly, the GSTT1 carriers include the
genotypes GSTT1 1n/1n and 1n/n2, with the GSTT1 n2/n2 genotype
indicating the deleted phenotype.
Statistics Allele frequencies were calculated according to the Hardy^
Weinberg equilibrium. The two-sided Fisher’s exact test was used to test
contingency tables for signi¢cant associations between patient groups and
control groups for the various enzymes as indicated in Results. Odds ratios
(OR) and 95% con¢dence intervals (95%CI) were calculated to measure
the strength of the observed associations. All statistical calculations
were done with Prism 3.0 software (GraphPad, San Diego, CA). Where
indicated the Bonferroni post test was used to adjust for multiple
comparisons: if k tests were done, the result of each test was considered
signi¢cant if po 0.05/k, thus ensuring an overall signi¢cance level of 5%.
RESULTS
Subjects The study group consisted of 327 patients and 235
controls. All patients and controls were typed for all enzymes
indicated, although due to experimental losses in some cases
the absolute number of typed subjects varies slightly for the
Table I. Conditions of RFLP-PCR
Gene Primera PCR pro¢leb RFLP enzymec Name of variant allele
CYP1A1 504CAGTGAAGAGGTGTAGCCGCTo30 55oC, 3000 MspI n2A (Msp)
[ref. 1]d 504TAGGAGTCTTGTCTCATGCCTo30 72oC, 10
35 cycles
CYP1B1 504AAC GTC ATG AGT GCC GTG TGTo30 57oC, 10 BfrI n3 (G)
[2]d 504GGC CGG TAC GTT CTC CAA ATCo30 72oC, 10
38 cycles
CYP2C19 504AAT TAC AAC CAG AGC TTG GCo30 58oC, 10 SmaI n2A (m1)
[3]d 504TAT CAC TTT CCATAA AAG CAA Go30 72oC, 10
35 cycles
CYP2E1 504CCC GTG AGC CAG TCG AGTo30 61oC, 10 RsaI, PstI n5B (C2)
[4]d 504ATACAG ACC CTT TTC CACo30 72oC, 10
30 cycles
GSTM1e 504GAACTCCCTGAAAAGCTAAAG 601C, 10 Homozygous absence of enzyme (null allele)
[5]d 504GTTGGGCTCAAATATACGGTGG 721C, 10
35 cycles
GST T1e 504TTCCTTACTGGTCCTCACATCTC 601C, 10 Homozygous absence of enzyme (null allele)
[6]d 504TCACCGGATCATGGCCAGCA 721C, 10
35 cycles
NQOR 504ATTTGAATTCGGGCGTCTGCTGo30 58oC, 10 Hinf1 Ser187 (null allele)
[7]d 504GAGACGCTAGCTCTGAACTGATo30 72oC,10
30 cycles
aPrimers used for PCR are listed as forward primer (upper line) and reverse primer (second line). Primer sequences were taken from the literature.
bAnnealing temperature and duration/extension temperature and duration/number of cycles. A denaturation step at 951C for 1 min preceded each cycle.
cEnzyme used to cut for determination of restriction fragment length polymorphism indicative of variant allele.
d[1] Hayashi et al (1991); [2] Bailey et al (1998); [3] de Morais et al (1994); [4] Persson et al (1993); [5, 6] Wiebel et al (1999); [7] Eickelmann et al (1994).
eIn order to verify DNA ampli¢cation in the assay, b-hemoglobin was co-ampli¢ed (data not shown).
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individual enzymes. Age distribution and gender were
similar for both patient and control group (Table III, A).
Approximately two-thirds of the patients had su¡ered an early
onset of disease, with women showing an earlier onset (mean at
age 19 for female patients versus mean at age 22 for male patients;
mean age for late onset was 55 and 52 y, respectively). Twenty-
seven men and 22 women patients su¡ered also from psoriatic
arthritis (PsA). Diagnosis was con¢rmed by X-ray and/or
scintigraphy. The gender ratio of this subgroup of patients was
no di¡erent from that of patients su¡ering from classical
psoriasis or healthy controls (Table III, B). Approximately one-
third of the patients reported a familial occurrence (¢rst-degree
relatives) of the disease. No statistically signi¢cant di¡erence
could be detected between men and women or psoriasis vulgaris
and PsA in this respect (Table III, B).
CYP1A1 variant alleles n2A and n2C are protective factors
for psoriasis In order to test for the hypothesis that genetic
variants of XMEs are associated with risk of psoriasis, we
determined the number of homozygous/heterozygous carriers of
a panel of phase I and phase II XMEs in psoriasis patients from
Germany and compared them to control persons. Genes were
chosen that cover several phase I and phase II enzymes, had been
suspected as relevant before, and include those enzymes that might
be relevant in the metabolism of alleged psoriatogenic drugs.
The number of carriers of a certain allele combination
(homozygous or heterozygous) was counted and analyzed using
contingency tables. The statistical evaluation of di¡erences
between patients and controls is compiled in Tables IV, V, and
VI. No signi¢cant di¡erences between patients and controls
could be observed for any phase I enzyme, with the exception
of CYP1A1 (see Tables IV and V). CYP1A1 is involved in the
hydroxylation of polycyclic aromatic hydrocarbons such as
benz[a]pyrene. The enzyme is inducible by, for example,
cigarette smoke or cruciferous vegetables. Several polymorphic
variants have been identi¢ed; we analyzed two, which result in
increased activity of the enzyme. The CYP1A1 reference
sequence is referred to as n1A. The rare variant allele CYP1A1
n2C (allele frequency of approximately 2%), responsible for a
higher activity of CYP1A1, has a single nucleotide exchange at
nucleotide 2455 that results in an isoleucin to valine exchange
(Hayashi et al, 1991). We also typed patients and controls for a
second variant allele of CYP1A1, the n2A allele. This allele has a
T3801C exchange (Petersen et al, 1991), resulting in easier
induction of the gene. The nucleotide exchanges resulting in
alleles n2A and n2C can be found alone or together in the gene
locus; the latter case is then called n2B. The risk potential of
CYP1A1 alleles n1A, n2A, and n2C is shown in Tables IV and V.
Table II. Primers for LightCycler
Gene Primera
Name of
variant
allele
CYP1A1b 504GAACTGCCACTTCAGCTGTCo30 n2C (IVA)
504ACCAGACCAGGTAGACAGAGTCo30
sensor: GAAGTGTATCGGTGAGACCGTTICC X
anchor: CTGGGAGGTCTTTCTCTTCC
TGGCTATC
aPrimers used for Lightcycler PCR are listed as forward primer (upper line) and
reverse primer (second line) plus sensor and anchor probe. Primers and PCR
conditions were designed/calculated by the company TIB MOLBIOL, Berlin,
Germany.
bSee Hayashi et al (1991).
Table III. Study population
A Men (%) Women (%) Mean age mena Mean age women
Patients 164 (50.3%) 162 (49.8%) 48.5 (14.4) 48.7 (15.5)
Controls 130 (57.0%) 98 (43.0%) 47.6 (13.1) 45.3 (13.5)
n.s. n.s.
B PsV (men)b PsV (women) PsA (men) PsA (women)
Onset ageco40 67 (82%) 56 (79%) 25 (93%) 17 (77%) n.s.
Onset age440 15 15 2 5 n.s.
Familial associationd 30 (34%) 34 (29%) 15 (52%) 10 (43%) n.s.
No familial association 58 49 14 13 n.s.
aMean age and SD (in parentheses) of indicated subjects in years.
bPsV, patients diagnosed with psoriasis vulgaris; PsA, patients diagnosed with psoriatic arthritis (including those who had PsA and PsV).
cNumber of patients where disease had started when they were under the age of 40, or over the age of 40.
dNumber of patients who reported next of kin to have psoriasis, too.
n.s., not signi¢cant.
Table IV. Genotype distribution for CYP1A1 reference sequence n1A and variant sequences n2A and n2C
Genotypea Patients Controls Exact p-value OR (95%CI)b
CYP1A1 n1A/n1A 272 (88%) 176 (76.8%) p¼ 0.0006 2.28 (1.4313.635)
CYP1A1 n1A/n2C 0 16 po 0.0001 
CYP1A1 n2C/n2C 0 1 n.d. 
CYP1A1 n1A/n2A 25 36 p¼ 0.0086 0.44 (0.27^0.81)
CYP1A1 n2C/n2A or n2Bc 9 0 n.d. 
CYP1A1 n2C/n2B 1 0 n.d. 
CYP1A1 n2A/n2A 0 0 n.d. 
CYP1A1 n2B/n2A or n2B/n2Cc 1 0 n.d. 
CYP1A1 n2B/n2B 0 0 n.d. 
aTwo single nucleotide exchanges at di¡erent positions in the CYP1A1 gene, i.e., alleles n2A and n2C, were typed for patients and controls. Numbers of individuals
carrying any of the nine possible allele combinations were counted. The reference sequence CYP1A1 n1A has no mutations (see Materials and Methods for nomenclature).
bFisher’s exact test on contigency tables of the numbers of carriers of this genotype versus the sum of all the others. OR and 95%CI. n.d., not done, as genotype too rare.
cFor this combination it is not possible to distinguish with our method of typing the alleles in two independent assays whether or not the nucleotide exchanges are on
the same chromosome or not.
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Variant alleles were more common in healthy control subjects. In
particular, 16 control subjects, but none of the patients, were
heterozygous carriers of variant allele CYP1A1 n2C (po0.0001).
Likewise, heterozygous carriers of CYP1A1 n2A were more
abundant in the controls (p¼ 0.0086) (see Table IV). The OR
for carriers of any of the two variant alleles was 0.44
(p¼ 0.0004), indicating a protective e¡ect of this variant allele in
comparison to CYP1A1 n1A (TableV).
With respect to the phase II enzymes, the analysis of carriers of
the three genes GSTM1, GSTT1, and NQOR did not yield a
signi¢cant result. ORs for NQORwere approximately the same,
even if slightly diluted, when we evaluated the ORs for allele
frequencies rather than number of carriers (compareTable V and
TableVI).
Combinations of several phase I and phase II enzyme
alleles have synergistic risk/protective e¡ects Few diseases
are caused by a single genetic defect; many more are
multifactorial. Exploring our data further, we analyzed whether
or not combinations of metabolizing enzyme variants are
conspicuously prevalent in psoriasis patients compared to
healthy controls. Only three combinations turned out to be
of possible interest. The combination of the reference allele
of 2C19 n1A [OR¼ 3.3 (1.36^9.66), p¼ 0.012] or GSTM1
[OR¼ 4.84 (1.29^18.13), p¼ 0.018] with CYP1A1 n1A is found
more often in patients than in controls. The high ORs are
suggestive of a susceptibility e¡ect for this genetic background,
although the 95%CI are rather broad. Note that no post test was
applied due to the explorative nature of the analysis. Also, the
combination of reference allele GSTM1 and heterozygosity for
NQOR gives an OR of 1.77 (1.02^3.07), p¼ 0.045.
CYP2C19 homozygosity as a risk factor for early onset
psoriasis Psoriasis can be divided into ‘‘early onset’’ and ‘‘late
onset’’ type of disease. As environmental factors may accumulate
in life, they conceivably could contribute more strongly in older
patients. Therefore, we tested early onset (before age 40) and late
onset (above age 40) psoriatic patients for di¡erences in XMEs.We
found that CYP2C19 n1A homozygotic carriers are found more
often in the early onset group (75%) than in the late onset group
(66%); this genotype confers a risk twice as high [OR¼ 2.20
(1.08^3.87), p¼ 0.0249]. The majority of our persons tested were
homozygous for CYP2C19 n1A, so for early onset the more
common genotype is associated with risk. Or, in other words,
the rarer CYP2C19 n2A protects from early onset of psoriasis. For
none of the other phase I and phase II enzymes could a di¡erence
between early and late onset patients be detected.
As CYP2C19 and CYP1A1 showed as susceptibility genes for
psoriasis, we tested for combinations of these genes in the early
and late onset subgroups. The presence of any of the variant
alleles of these two enzymes turned out to be a protective factor
for early onset psoriasis [OR¼ 0.52 (0.30^0.91), p¼ 0.023]
compared to late onset patients. This is signi¢cant, even after
Bonferroni post testing.
CYP2C19 heterozygosity protects from PsA PsA is a form
of the disease with involvement of the inner epithelia.
Altogether, 23% of the female patients and 31% of the male
patients had PsA. We tested for links of certain gene
polymorphisms with PsA. Again CYP2C19 came up.
Heterozygosity for CYP2C19 n1An2A appears to be a risk factor
for psoriasis vulgaris: 45 patients (26%) were heterozygous, and
only eight (12%) of the patients su¡ering also from PsA
[OR¼ 2.5 (1.15^5.56), p¼ 0.024].
TableV. Genotype distribution of the described XMEs in patients and control individuals
Patients Control individuals
Enzymea
Homozygous
RefS
Heterozygous Homozygous
VarS
Homozygous
RefS
Heterozygous Homozygous
VarS p-value
ORb (95%CI)
of VarS
CYP1A1 n1A/n2A
or 2C
272 (88.3%) 36 (11.7%) 0 (0%) 176 (76.8%) 53 (23.1%) 1 (0.4%) 0.0004n 0.44 (0.270.68)
CYP1B1 n1/n3 93 (29.5%) 146 (46.3%) 76 (24.1%) 75 (31.9%) 113 (48.1%) 47 (20.0%) 0.571 1.12 (0.781.63)
CYP2C19 n1A/n2A 235 (73.6%) 75 (23.5%) 9 (2.8%) 163 (69.6%) 66 (28.2%) 5 (2.1%) 0.338 0.82 (0.561.19)
CYP2E1 n1A/n5B 306 (95.6%) 14 (4.3%) 0 222 (94.4%) 12 (5.1%) 1 (0.4%) 0.554 1.28 (0.592.77)
GST M1 131 (49.1%) 136 (50.9%) 89 (40.3%) 132 (59.7%) 0.055 0.70 (0.481.00)
GST T1 206 (77.4%) 60 (22.6%) 184 (80.0%) 46 (20.0%) 0.511 1.16 (0.751.79)
NQOR 209 (66.8%) 91 (29.1%) 13 (4.1%) 169 (72.2%) 52 (22.2%) 13 (5.6%) 0.191 1.29 (0.891.87)
aEnzymes with known polymorphisms were genotyped for approximately 300 psoriasis patients and approximately 230 controls. See Materials and Methods for details.
Number of carriers either homozygous for the RefS, heterozygous for RefS andVarS, or homozygous forVarS are shown. Genotype frequencies are given in parentheses.
bOR for the carriers of VarS (heterozygote plus homozygote) in patients versus controls was calculated by Fisher’s exact test. 95%CI were calculated with GraphPad
PrismTM using the approximation by Katz et al (1978). Probability values p and ORs are shown.
nSigni¢cant after Bonferroni post test for k¼ 8 (po0.05/k, i.e., po0.000625).
TableVI. Allele frequencies of XMEs in psoriasis patients and healthy volunteers
Patients Controls
Enzymea RefSb VarSb RefS VarS p-value OR (95%CI) of variant allelec
1A1 (n2C) 0.991 (618) 0.019 (12) 0.959 (441) 0.041 (19) 0.041 0.44 (0.210.92)
1A1 (n2A) 0.932 (585) 0.068 (43) 0.932 (431) 0.079 (37) 0.557 0.85 (0.541.35)
1B1 0.527 (332) 0.473 (295) 0.560 (263) 0.440 (207) 0.328 1.13 (0.891.44)
2C19 0.854 (545) 0.146 (93) 0.835 (392) 0.165 (76) 0.448 0.88 (0.621.22)
2E1 0.978 (626) 0.022 (14) 0.970 (456) 0.030 (14) 0.442 0.72 (0.341.54)
NQOR 0.813 (509) 0.187 (117) 0.833 (390) 0.167 (78) 0.425 1.15 (0.841.57)
aEnzymes were genotyped by RFLP-PCR for reference and variant allele.
bFrequency of reference allele (RefS) and variant allele (VarS) was calculated from genotyped patients assuming HardyWeinberg equilibrium. Absolute numbers of
alleles are given in parentheses.
cORs for the number of reference alleles and of variant alleles in patients and controls were calculated by Fisher’s exact test. 95%CI were calculated. ORo1 indicates a
protective e¡ect associated with the respective variant allele.
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DISCUSSION
In a healthy person, the destructive power of autoreactive T cells
is kept under control. In autoimmune diseases this immunologic
tolerance is broken, and T cells play a pivotal role in the patholo-
gic processes (Chang et al, 1994). Although it is not entirely clear
whether psoriasis is an autoimmune disease, it has many autoim-
mune features, and T cells are known to be essential. One possi-
bility to break immunologic tolerance is the generation of novel
self-peptides by changes in antigen processing, e.g., via environ-
mental agents. Chemicals or their protein-reactive metabolites
can either act as haptens themselves or change the normal degra-
dation of proteins. An increasing body of evidence supports this
notion. Drugs like procainamide or propylthiouracil, chemicals
like trinitrophenyl derivatives, and even metal salts have been
shown to be able to break tolerance and activate T cells (reviewed
in Griem et al, 1997). Could such a mechanism also be underlying
the susceptibility to psoriasis, a disease that can be triggered by
chemicals and drugs?
Susceptibility to autoimmune diseases is in part genetically de-
termined. Psoriasis is no exception. Good associations are found
with certain HLA class I and class II alleles, which is not surpri-
sing given the role of these molecules in the presentation of anti-
gen peptides toT cells (Henseler and Christophers, 1985; Schmitt-
Egenolf et al, 1993).The e¡ects of chemical/environmental triggers
of psoriasis can vary, suggestive of genetic factors (Baker, 2000).
We look at XMEs as such possible factors.
We analyzed the genes of four polymorphic phase I XMEs and
three phase II enzymes in more than 300 patients with psoriasis.
Our results are in good agreement with allele frequencies re-
ported in the literature for the various enzymes, indicating that
neither patients nor control persons in our study are a biased
genetic subgroup of the German population (Garte et al, 2001b).
The number of persons carrying any of the two rare variant
alleles of CYP1A1 for which we tested was signi¢cantly larger in
the healthy control group; the OR for this e¡ect was 0.44, indi-
cating an almost double protection. The e¡ect was highly signi¢-
cant. In other words, the reference allele CYP1A1 n1A, the
common allele carried by the majority of Caucasians, is signi¢-
cantly more abundant in psoriatic patients. Moreover, when ex-
ploring combinations of enzymes more risk and protective
factors became evident. Combinations of the common CYP1A1
n1A reference allele with CYP2C19 n1A or GSTM1 gave ORs of
more than 3 and 4, respectively. The p-values for these combi-
nations below 0.05 are suggestive and results can be used in
further hypothesis driven epidemiologic studies.
The CYP1A1 n1A reference allele codes for an enyzme of lower
activity than the variant form n2C. The other CYP1A1 variant
(n2A), characterized by an additional Msp restriction site, has a
higher inducibility by polyaromatic hydrocarbons. Intriguingly,
in humans CYP1A1 is not expressed in the liver, but in lung,
intestine, skin, and lymphocytes (Krishna and Klotz, 1994).
CYP1A2, which catalyzes the same type of reactions as CYP1A1,
is absent in extrahepatic tissues. Thus, when both CYP1A1 refer-
ence alleles are present in nonhepatic tissues, the initial oxidation
of xenobiotics is lower than with the variant forms, possibly lead-
ing to accumulation of xenobiotics and conceivably a higher
chance of aberrant antigen formation. A higher metabolic rate
provided by the variant alleles then seems to have a protective
e¡ect as shown by our results.
Before the advent of techniques allowing di¡erent CYP alleles
to be distinguished, a number of in vitro functional studies were
published suggestive of a link between the activity of aryl hydro-
carbon hydroxylase ^ the old term for CYP1A1 ^ and psoriasis
(Chapman et al, 1979; Shuster et al, 1980; Goerz and Merk, 1992).
Parallel to our ¢ndings, in these studies psoriasis was found to be
associated with a lower activity/inducibility of aryl hydrocarbon
hydroxylase. The data were controversial, however (Bickers et al,
1984), and due to the technical impossibility then to identify
distinct enzymes/alleles, their interpretation was limited. Our
¢ndings provide a new angle on these data, and it would be
interesting to repeat some of the functional induction assays with
genetically de¢ned patient groups.
For the autoimmune disease systemic lupus erythematosus, an
association with GSTM1 null allele has been shown (Ollier et al,
1996). The enzymatic action of GSTcan yield DNA- and protein-
reactive metabolites. It is tempting to speculate that in psoriasis
the GSTM1 pathway might yield protein-reactive substances that
can cause generation of neoantigens. Detoxi¢cation by NQOR is
accompanied by the generation of reactive oxygen species, which
are known to activate macrophages, key cells in antigen presenta-
tion. The combinations of GSTM1null/NQORhet gave an OR of
1.77 with p¼ 0.04. This is not signi¢cant when the Bonferroni
statistical adjustment for multiple testing is used (in our explora-
tion of eight enzymes giving 33 combinations k¼ 33, necessitat-
ing lowering a to 0.0015). Considering functional assays or
metabolic pathways, however, these values are suggestive, and
we would take these enzymes into consideration nonetheless.
Xenobiotics can be metabolized not only in liver cells but also
extrahepatically. There is evidence that metabolism in antigen
presenting phagocytes is involved in systemic adverse immune
reactions to procainamide, propylthiouracil, and gold(I) thio-
malate (Kubicka-Muranyi et al, 1993; Goebel et al, 1995; von
Schmiedeberg et al, 1996). Further functional studies in the meta-
bolic and immunogenic pathways of psoriasis-inducing drugs
would be necessary to clarify whether and how such scenarios
play a role in psoriasis pathogenesis.
Our patient group showed two distinct subpopulations. In the
majority of patients, disease onset of psoriasis had occurred in
their teens; in the other group, onset occurred later in life, at an
average age of 50. Conceivably, the latter group might have had a
bigger chance of exposure to triggering factors, or accumulated
xenobiotics in life. As expected, the e¡ects of CYP1A1 remained;
however, they were exacerbated for late onset if patients were also
homozygotic carriers of the CYP2C19 n1A reference allele.What
could explain this e¡ect? CYP2C19 is an enzyme responsible for
the metabolizing of, among others, propranolol and proguanil, a
beta-blocker and an antimalarial, respectively. This ¢ts with our
idea that triggering of psoriasis by such drugs might correlate
with the way the body metabolizes them. The rare variant allele
CYP2C19 n2A is associated with poor metabolic activity. Unfor-
tunately, it was impossible to link psoriasis, genotype, and ana-
mnestic data on drug usage over lifetime, because the memory
of the patients about the drugs they had taken was incomplete.
In particular, a statistically signi¢cant link to the beta-blocker
propranolol could not be established, as only seven patients
reported having taken this drug. Establishing such a link with
an analytical epidemiologic study would be necessary to clarify
whether metabolizing xenobiotics at a higher rate by CYP2C19
is a step towards the disease.
Although they have broad and overlapping substrate speci¢-
cities, the Km values of single CYP450 enzymes can dictate the
limiting step in metabolizing a chemical. For instance, only
CYP2C19, but not CYP3A4, metabolizes diazepam in vivo (Kato
andYamazoe, 1994), although both are capable of doing so in vitro.
Eventually, it has to be determined, for each xenobiotic, which
enzymes participate in metabolizing. Our explorative approach
thus can only correlate genotype and risk, but is of limited value
to pinpoint the culprit drugs.
Whereas heterozygosity for the CYP2C19 alleles was a risk fac-
tor for late onset of psoriasis, the same genotype turned out to be
a protective factor against PsA. In good agreement with the lit-
erature, about one-third of our patients su¡ered from PsA, usual-
ly in addition to psoriasis vulgaris (Scarpa et al, 1984). As
described above, the variant 2C19 allele codes for an enzyme of
lower activity. Interestingly, in Japan, where the variant isoform
is about 10 times more common (approximately 12%^23%), the
incidence of arthropathic psoriasis is reportedly lower than in
Caucasians, only 12.7% (Hukuda et al, 2001).
In conclusion, we have shown that some XMEs, in particular
CYP1A1 and CYP2C19, can be susceptibility factors in psoriasis,
adding these genes to those already considered important in the
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pathomechanism of the disease (Burden et al, 1998; Elder et al,
2001). Our ¢ndings supply important background information
to tackle the problem of how metabolizing xenobiotic substances
can be linked to psoriasis and eventually whether environmental
factors interfere with antigen presentation by the immune sys-
tem. Even though our data do not have a direct therapeutic im-
pact, they reassert the medical necessity of care in the prescription
of certain drugs, like beta-blockers, to psoriatic patients (Gold
et al, 1988).
One last caveat: as we could see in our study, a genotype asso-
ciated with an increased risk for situation A (here: CYP2C19 and
late onset psoriasis) might at the same time be associated with a
decreased risk for situation B (here: CYP2C19 and PsA). There-
fore, it cannot be concluded that there is an ideal genotype for
all situations. This is also true for other diseases and genotypes.
Genetic variation in humans is an important factor in being ‘‘pre-
pared’’ for all evolutionary challenges that might yet come.
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